• Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study

    The Xpert™ MTB/RIF (XP) has a higher sensitivity than sputum smear microscopy (70% versus 35%) for TB diagnosis and has been endorsed by the WHO for TB high burden countries to increase case finding among HIV co-infected presumptive TB patients. Its impact on the diagnosis of smear-negative TB in a routine care setting is unclear. We determined the change in diagnosis, treatment and mortality of smear-negative presumptive TB with routine use of Xpert MTB/RIF (XP).

    Sabine M. Hermans, Juliet A. Babirye, Olive Mbabazi, Francis Kakooza, Robert Colebunders, Barbara Castelnuovo, Christine Sekaggya-Wiltshire, Rosalind Parkes-Ratanshi and Yukari C. Manabe

    BMC Infect Dis. 2017 Jun 16;17(1):433


  • The Impact of Road Development on Household Welfare in Rural Papua New Guinea

    In this paper we estimate the impact of road development on household welfare in rural Papua New Guinea over the period between 1996 and 2010, using two cross-sectional household surveys and corresponding road maps. To deal with endogenous placement of road infrastructure programs we employ a correlated random effects model that corrects for location-specific changes in road quality. We also use a newly developed quantile regression method to investigate whether road works are pro-poor. Estimates show that investments in sealing roads to nearest towns led to higher consumption levels and housing quality, and to less reliance on subsistence farming. Effects are stronger among poor, less educated, and female-led households.

    Martin Wiegand, Eric Koomen, Menno (M.) Pradhan, Christopher Edmonds

    Tinbergen Institute Discussion Paper, TI 2017-076/V

  • The Impact of Expanding Access to Early Childhood Education Services in Rural Indonesia

    This paper examines the effects of an intervention that expanded access to low-cost, government-sponsored, community-based playgroups in rural Indonesia. Instrumental variables and difference-in-differences models indicate that while the intervention raised enrollment rates and durations of enrollment for everyone, on average, there was little impact on child development. The two models correspond to different durations of project exposure. The difference-in-differences model captures greater exposure and shows that there are modest and sustained impacts on child development—especially for children from more disadvantaged backgrounds. There is also evidence that the intervention encouraged substitution away from other services, such as kindergartens.

  • Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study

    The Xpert™ MTB/RIF (XP) has a higher sensitivity than sputum smear microscopy (70% versus 35%) for TB diagnosis and has been endorsed by the WHO for TB high burden countries to increase case finding among HIV co-infected presumptive TB patients. Its impact on the diagnosis of smear-negative TB in a routine care setting is unclear. We determined the change in diagnosis, treatment and mortality of smear-negative presumptive TB with routine use of Xpert MTB/RIF (XP).

    Sabine M. Hermans, Juliet A. Babirye, Olive Mbabazi, Francis Kakooza, Robert Colebunders, Barbara Castelnuovo, Christine Sekaggya-Wiltshire, Rosalind Parkes-Ratanshi and Yukari C. Manabe

    BMC Infectious Diseases DOI: 10.1186/s12879-017-2534-2

  • An easy tool to assess ventilation in health facilities as part of air-borne transmission prevention: a cross-sectional survey from Uganda

    Brouwer M, Katamba A, Katabira ET, van Leth F.
    BMC Infect Dis. 2017 May 3;17(1):325. doi: 10.1186/s12879-017-2425-6.

  • Tuberculosis resistance-conferring mutations with fitness cost among HIV-positive individuals in Uganda

    Ssengooba W, Lukoye D, Meehan CJ, Kateete DP, Joloba ML, de Jong BC, Cobelens FG, van Leth F
    Int J Tuberc Lung Dis. 2017 May 1;21(5):531-536. doi: 10.5588/ijtld.16.0544.

  • Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure

    Authored by: Dedicoat MJ, Günther G, Crudu V, Duarte R, Gualano G, Magis-Escurra C, Rumetshofer R, Skrahina A, Spinu V, Tiberi S, Viiklepp P, van Leth F, Lange C; TBNET.
    Am J Respir Crit Care Med. 2017 Mar 21. doi: 10.1164/rccm.201612-2585LE. [Epub ahead of print] No abstract available.

  • Rapid assessment of antimicrobial resistance prevalence using a Lot Quality Assurance sampling approach

    Authored by: van Leth F, den Heijer C, Beerepoot M, Stobberingh E, Geerlings S, Schultsz C.
    Future Microbiol. 2017 Mar 24. doi: 10.2217/fmb-2016-0170. [Epub ahead of print]

  • Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review.

    Authored by: Bruins WS, van Leth F.
    Infect Dis (Lond). 2017 Mar;49(3):161-169. doi: 10.1080/23744235.2016.1262059.

  • Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial

    Authored by: Manabe YC, Worodria W, van Leth F, Mayanja-Kizza H, Traore AN, Ferro J, Pakker N, Frank M, Grobusch MP, Colebunders R, Cobelens F.
    Am J Trop Med Hyg. 2016 Dec 7;95(6):1265-1271.

  • More on Treatment Outcomes in Multidrug-Resistant Tuberculosis

    Authored by: Lange C, Günther G, van Leth F; TBNET.
    N Engl J Med. 2016 Dec 29;375(26):2611. doi: 10.1056/NEJMc1613123. No abstract available.

  • Antimicrobial resistance in uropathogens and appropriateness of empirical treatment: a population-based surveillance study in Indonesia

    Authored by: Sugianli AK, Ginting F, Kusumawati RL, Pranggono EH, Pasaribu AP, Gronthoud F, Geerlings S, Parwati I, De Jong MD, Van Leth F, Schultsz C.
    J Antimicrob Chemother. 2017 Jan 30. pii: dkw578. doi: 10.1093/jac/dkw578. [Epub ahead of print]

  • Increased brain-predicted aging in treated HIV disease

    Authored by: James H. Cole, PhD; Jonathan Underwood, MBBS, BSc; Matthan W.A. Caan, PhD; Davide De Francesco, MSc; Rosan A. van Zoest, MD; Robert Leech, PhD; Ferdinand W.N.M. Wit, PhD; Peter Portegies, PhD; Gert J. Geurtsen, PhD; Ben A. Schmand, PhD; Maarten F. Schim van der Loeff, PhD; Claudio Franceschi, PhD; Caroline A. Sabin, PhD;  Charles B.L.M. Majoie, MD, PhD; Alan Winston, MD, PhD; Peter Reiss, MD, PhD; David J. Sharp, PhD. On behalf of the COBRA collaboration.
    In: Neurology. DOI: 10.1212/WNL.0000000000003790

  • Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts

    Authored by: Rimke Bijker, Awachana Jiamsakul, Cissy Kityo, Sasisopin Kiertiburanakul, Margaret Siwale, Praphan Phanuphak, Sulaimon Akanmu, Romanee Chaiwarith, Ferdinand W Wit, Benedict LH Sim, Tamara Sonia Boender, Rossana Ditangco, Tobias F Rinke de Wit, Annette H Sohn, Raph L Hamers.
    In: Journal of the International AIDS Society 2017, 20:21218

    Our understanding of how to achieve optimal long-term adherence to antiretroviral therapy (ART) in settings where the burden of HIV disease is highest remains limited. We compared levels and determinants of adherence over time between HIV-positive persons receiving ART who were enrolled in a bi-regional cohort in sub-Saharan Africa and Asia.

  • Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study

    Authored by: Helen Cox, Lindy Dickson-Hall, Norbert Ndjeka, Anja van’t Hoog, Alison Grant, Frank Cobelens, Wendy Stevens, Mark Nicol.
    In: PLoS Med 14(2): e1002238. doi:10.1371/journal.pmed.1002238

    South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,734 patients diagnosed in 2014. The number of diagnosed patients has increased substantially with the introduction of the Xpert MTB/RIF test, used for tuberculosis (TB) diagnosis for all patients with presumptive TB. Routine aggregate data suggest a large treatment gap (pre-treatment loss to follow-up) between the numbers of patients with laboratory-confirmed RR-TB and those reported to have started second-line treatment. We aimed to assess the impact of Xpert MTB/RIF implementation on the delay to treatment initiation and loss to follow-up before second-line treatment for RR-TB across South Africa.

  • The evolving landscape of HIV drug resistance diagnosis for expanding testing in resource-limited settings.

    Authored by: Inzaule, S.C., Hamers, R.L., Paredes, R., Yang, C., Schuurman, R. and Rinke de Wit, T.F.
    In: AIDS Reviews, in press, 2017.

  • Uptake and acceptability of oral HIV Self-Testing among community pharmacy clients in Kenya: a feasibility study

    Authored by: Mugo, P., Micheni, M., Shangala, J., Hanif, M., Graham, S., Rinke de Wit, T.F., and Sanders, E.
    In: PLOS One, in press, 2017.

  • Determinants of adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts

    Authored by: Bijker, R., Jiamsaku, A., Kityo, C.M., Kiertiburanakul, S., Siwale, M., Phanuphak, P., Akanmu, S., Chaiwarit, R., Wit, F., Sim, B.L.H., Boender, T.S., Ditangco, R., Rinke de Wit, T.F., Sohn, A.H. and Hamers, R.L. . J.
    In: Int. AIDS Soc., in press, 2017.

  • Cigarette Smoking and Inflammation, Monocyte Activation, and Coagulation in HIV-Infected Individuals Receiving Antiretroviral Therapy, Compared With Uninfected Individuals

    Authored by: Kooij KW, Wit FW, Booiman T, van der Valk M, Schim van der Loeff MF, Kootstra NA, Reiss P; AGEhIV Cohort Study Group.
    In: J Infect Dis. 2016 Dec 15;214(12):1817-1821.

    Smoking may affect cardiovascular disease risk more strongly in human immunodeficiency virus (HIV)-infected individuals than HIV-uninfected individuals. We hypothesized that an interaction at the level of the immune system may contribute to this increased risk. We assessed soluble markers of inflammation (high-sensitivity C-reactive protein [hsCRP]), immune activation (soluble [s]CD14 and sCD163), and coagulation (D-dimer) in HIV-infected and uninfected never, former, and current smokers. Smoking was independently associated with higher hsCRP levels and lower sCD163 levels and was borderline significantly associated with higher sCD14 and D-dimer levels. We found no evidence of a differential effect of smoking in HIV-infected individuals as compared to uninfected individuals.

  • Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

    Authored by: Alffenaar JC, Akkerman OW, Anthony RM, Tiberi S, Heysell S, Grobusch MP, Cobelens FG, Van Soolingen D.
    In: Expert Rev Anti Infect Ther 2017;15:11-21.

    Success rates for treatment of extensively drug resistant tuberculosis (XDR-TB) are low due to limited treatment options, delayed diagnosis and inadequate health care infrastructure. Areas covered: This review analyses existing programmes of prevention, diagnosis and treatment of XDR-TB. Improved diagnostic procedures and rapid molecular tests help to select appropriate drugs and dosages. Drugs dosages can be further tailored to the specific conditions of the patient based on quantitative susceptibility testing of the M. tuberculosis isolate and use of therapeutic drug monitoring. Pharmacovigilance is important for preserving activity of the novel drugs bedaquiline and delamanid. Furthermore, biomarkers of treatment response must be developed and validated to guide therapeutic decisions. Expert commentary: Given the currently poor treatment outcomes and the association of XDR-TB with HIV in endemic regions, a more patient oriented approach regarding diagnostics, drug selection and tailoring and treatment evaluation will improve treatment outcome. The different areas of expertise should be covered by a multidisciplinary team and may involve the transition of patients from hospitalized to home or community-based treatment.

  • Assessment of a 96-well plate assay of quantitative drug susceptibility testing for Mycobacterium tuberculosis complex in China

    Authored by: Xia H, Zheng Y, Zhao B, Van den Hof S, Cobelens F, Zhao Y.
    In: PLoS One 2017;12:e0169413.

  • From latent to patent: rethinking prediction of tuberculosis disease in infected individuals

    Authored by: Cobelens F, Kik S, Esmail H, Cirillo DM, Lienhardt C, Matteelli A.
    In: Lancet Resp Med 2016.

    Tuberculosis remains a major global health problem. It is estimated that more than 2 billion people around the world are latently infected with Mycobacterium tuberculosis, with a lifetime risk of progression to tuberculosis disease of 5–15%.1 The WHO End Tuberculosis strategy, which aims to end tuberculosis as a major health problem by 2035, calls for reducing this huge reservoir for transmission by scaling up preventive therapy of individuals with latent tuberculosis infection. Preventive therapy with daily isoniazid offers 60–90% protection and combination therapies (daily isoniazid-rifampicin, weekly isoniazid-rifapentine) are effective alternatives.

    Ankeiler: In this viewpoint paper Frank Cobelens and co-authors propose a new paradigm for understanding testing for latent tuberculosis infection (LTBI). It distinguishes testing for persistent TB infection from testing for very early clinical („incipient”) TB and argues that only tests that belong to the latter category will be sufficiently predictive for clinical tuberculosis developing within a 2-year timeframe to be used for large-scale test-and-treat of LTBI. This notion has implications for the design, evaluation and application of new LTBI tests.

  • It takes more than a sensitive test to find more tuberculosis cases

    Authored by: Trajman A, Cobelens F.
    In: Lancet Infect Dis, 2017 5 Jan.

    Of the 9·6 million people estimated to have developed tuberculosis in 2014, only 63% of cases were reported.1 This gap partly reflects low rates of case detection and calls for models of intensified case finding at the community level based on effective and feasible screening strategies and technologies.

    Ankeiler: In this comment Anete Trajman and Frank Cobelens discuss the limitations of pragmatic trials of enhanced/active case finding for tuberculosis, in particular the sensitivity of the results to variation in existing practice and the importance of cost-effectiveness.

  • Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model

    Authored by: Fofana M, Shrestha S, Knight G, Cohen T, White R, Cobelens F, Dowdy D.
    In: Antimicrob Agents Chemother, 2016 Dec 12. pii: AAC.00498-16.

  • Health Seeking Behaviour among Individuals with Presumptive Tuberculosis in Zambia

    Authored by: Chanda-Kapata P, Kapata N, Masiye F, Maboshe M, Klinkenberg E, Cobelens F, Grobusch MP.
    In: PLoS One 2016;11:e0163975.

  • Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study

    Authored by: The PASER group, Ravi Gupta, Raph Hamers et al.
    In: The Lancet online 2016 November 30,

    HIV-1 drug resistance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been identified in sub-Saharan Africa in patients with virological failure of first-line combination antiretroviral therapy (ART) containing the modern nucleoside reverse transcriptase inhibitor tenofovir. We aimed to investigate the prevalence and correlates of thymidine analogue mutations (TAM) in patients with virological failure of first-line tenofovir-containing ART.

  • Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants

    Authored by: NCD Risk Factor Collaboration (NCD-RisC)*
    In: The Lancet online 2016 November 15, doi: 10.1016/S0140-6736(16)31919-5
    *Hendriks, M. e.a.

    Raised blood pressure is an important risk factor for cardiovascular diseases and chronic kidney disease. We estimated worldwide trends in mean systolic and mean diastolic blood pressure, and the prevalence of, and number of people with, raised blood pressure, defined as systolic blood pressure of 140 mm Hg or higher or diastolic blood pressure of 90 mm Hg or higher.


  • Tradeoffs in Bedaquiline Introduction Policies: A Model Based Analysis

    Authored by: Kunkel A, Cobelens F, Cohen T.
    In: PLoS Med 2016;13:e1002142.

    Bedaquilline, a new drug to treat tuberculosis, is currently only recommended for use in patients with advanced forms of drug resistance (XDR-TB and “pre-XDR-TB’). In a collaboration with Yale School of Public Health we used mathematical modeling to predict the effects of alternative scenarios of introducing bedaquilline. We showed that expanding bedaquiline access to all patients with MDR TB would have the best trade-offs for patients’ health, protection of background MDR TB drugs and reduction in transmission, although it would likely result in greater resistance to bedaquiline. This means that WHO should consider less restrictive use of this drug. Read more

  • Do Xpert MTB/RIF Cycle Threshold Values Provide Information about Patient Delays for Tuberculosis Diagnosis?

    Authored by: Ssengooba W, Respeito D, Mambuque E, Blanco S, Bulo H, Mandomando I, de Jong BC, Cobelens FG, García-Basteiro AL.
    In: PLoS One 2016;11:e0162833.

    In this study done in Mozambique we analyzed whether information about sputum bacterial burden provided by the GeneXpert diagnostic test is associated with diagnostic delays among tuberculosis patients, and could thereby be used to monitor such delays as an indicator of the quality of TB control efforts. We found no such association. Read more

  • Limited Benefit of the New Shorter MDR-TB Regimen in Europe

    Authored by: Lange C, Duarte R, Fréchet-Jachym M, Guenther G, Guglielmetti L, Olaru ID, Oliveira O, Rumetshofer R, Veziris N, van Leth F; European MDR-TB database collaboration.
    In: Am J Respir Crit Care Med. 2016 Sep 29. [Epub ahead of print] No abstract available.

  • Population impact of factors associated with prevalent pulmonary tuberculosis in Tanzania

    Authored by: Senkoro M, Kumar AM, Chinnakali P, Mfinanga SG, Egwaga S, Kamara V, van Leth F, Hinderaker SG.
    In: Int J Tuberc Lung Dis. 2016 Oct;20(10):1326-1333.


  • An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype

    Authored by: Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Nelson M, Montaner JS, Lane HC, Larder BA; RDI Data and Study Group.
    In: J Antimicrob Chemother. 2016 Oct;71(10):2928-37. PMID: 27330070

  • Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa

    Authored by: Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, Siwale M, Nankya I, Kaudha E, Akanmu AS, Botes ME, Steegen K, Calis JC, Rinke de Wit TF, Sigaloff KC.
    In: J Antimicrob Chemother. 2016 Oct;71(10):2918-27. PMID: 27342546

  • Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa

    Authored by: Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, Labib Maksimos EE, Balinda SN, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Stevens W, Rinke de Wit TF, Sigaloff KC.
    In: J Infect Dis. 2016 Sep 15;214(6):873-83. PMID: 27402780

  • Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa

    Authored by: Inzaule SC, Ondoa P, Peter T, Mugyenyi PN, Stevens WS, de Wit TF, Hamers RL.
    In: Lancet Infect Dis. 2016 Aug 25. pii: S1473-3099(16)30118-9. doi: 10.1016/S1473-3099(16)30118-9. PMID: 27569762

  • Next-generation sequencing and HIV drug resistance surveillance

    Authored by: Hamers RL, Paredes R.
    In: Lancet HIV. 2016 Sep 14. pii: S2352-3018(16)30151-5. doi: 10.1016/S2352-3018(16)30151-5. PMID: 27658866

  • Prevalence of pulmonary tuberculosis in adult population of Tanzania: a national survey, 2012

    Authored by: Senkoro M, Mfinanga S, Egwaga S, Mtandu R, Kamara DV, Basra D, Fundikira L, Kahwa A, Shirima R, Range N, Hinderaker SG , van Leth F
    In: Int J Tuberc Lung Dis. 2016 Aug;20(8):1014-21. doi: 10.5588/ijtld.15.0340

  • Intention of physicians to implement guidelines for screening and treatment of latent tuberculosis infection in HIV-infected patients in The Netherlands: a mixed-method design

    Authored by: Evenblij K, Verbon A, van Leth F
    In: BMC Public Health. 2016 Sep 1;16(1):915. doi: 10.1186/s12889-016-3539-2

  • Anaemia in Patients with HIV-associated tuberculosis in South Africa: Predictive/prognostic value, aetiologies and treatment

    Authored by: Andrew D. Kerkhoff
    Thesis Universiteit van Amsterdam
    Promotores: F.G.J. Cobelens, S.D. Lawn
    Date of thesis defense: 21/06/2016

    Tuberculosis remains the leading cause of death among people living with HIV in sub-Saharan Africa and worldwide. This thesis found that moderate or severe anaemia was highly predictive of both prevalent and incident tuberculosis among ambulatory outpatients as well as hospitalised in-patients in South Africa and was also a very strong independent predictor of mortality. Read more

  • Host and disease factors are associated with cognitive function in European HIV infected adults prior to initiation of antiretroviral therapy

    Authored by: Winston A., Stöhr W., Antinori A., Arenas Pinto A., Llibre J. M., Amieva H., Cabié A., Williams I., Di Perri G., Tellez M. J., Rockstroh J., Babiker A., Pozniak A., Raffi F., Richert L.

  • A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow Fever Specific Neutralizing Antibody and T Cell Responses after Vaccination

    Authored by: Wieten Rosanne W., Jonker Emile F. F., van Leeuwen Ester M. M., Remmerswaal Ester B. M., ten Berge Ineke J. M., de Visser Adriëtte W., van Genderen Perry J. J., Goorhuis Abraham, Visser Leo G., Grobusch Martin P., de Bree Godelieve J.
    In: PLOS ONE 11(3), 2016, p.e0149871 .

  • Higher prevalence of hypertension in HIV 1 infected patients on combination antiretroviral therapy is associated with changes in body composition and prior stavudine exposure

    Authored by: van Zoest Rosan A., Wit Ferdinand W., Kooij Katherine W., van der Valk Marc, Schouten Judith, Kootstra Neeltje A., Wiersinga W. Joost, Prins Maria, van den Born Bert Jan H., Reiss Peter.
    In: CLINICAL INFECTIOUS DISEASES [aheadofprint], 2016, p. .

  • Impact evaluation of a community based intervention for prevention of cardiovascular diseases in the slums of Nairobi: the SCALE UP study

    Authored by: van de Vijver Steven, Oti Samuel Oji, Gomez Gabriela B., Agyemang Charles, Egondi Thaddaeus, van Charante Eric Moll, Brewster Lizzy M., Hankins Catherine, Tanovic Zlata, Ezeh Alex, Kyobutungi Catherine, Stronks Karien.
    In: GLOBAL HEALTH ACTION 9, 2016, p.30922 .

  • Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV Infected Children

    Authored by: van Dalen Yvonne W., Blokhuis Charlotte, Cohen Sophie, ter Stege Jacqueline A., Teunissen Charlotte E., Kuhle Jens, Kootstra Neeltje A., Scherpbier Henriette J., Kuijpers Taco W., Reiss Peter, Majoie Charles B. L. M., Caan Matthan W. A., Pajkrt Dasja.
    In: MEDICINE 95(12), 2016, p.e3093 .

  • Non Typhoidal Salmonella Colonization in Chickens and Humans in the Mekong Delta of Vietnam

    Authored by: Trung N. V., Carrique Mas J. J., Nghia N. H., Tu L. T. P., Mai H. H., Tuyen H. T., Campbell J., Nhung N. T., Nhung H. N., Minh P. V., Chieu T. T. B., Hieu T. Q., Mai N. T. N., Baker S., Wagenaar J. A., Hoa N. T., Schultsz C.
    In: ZOONOSES AND PUBLIC HEALTH [aheadofprint], 2016, p. .

  • White matter hyperintensities in relation to cognition in HIV infected men with sustained suppressed viral load on cART

    Authored by: Su Tanja, Wit Ferdinand W. N. M., Caan Matthan W. A., Schouten Judith, Prins Maria, Geurtsen Gert J., Cole James H., Sharp David J., Richard Edo, Reneman Liesbeth, Portegies Peter, Reiss Peter, Majoie Charles B.
    In: AIDS [aheadofprint], 2016, p. .

  • Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus

    Authored by: Sohn Elliott H., van Dijk Hille W., Jiao Chunhua, Kok Pauline H. B., Jeong Woojin, Demirkaya Nazli, Garmager Allison, Wit Ferdinand, Kucukevcilioglu Murat, van Velthoven Mirjam E. J., DeVries J. Hans, Mullins Robert F., Kuehn Markus H., Schlingemann Reinier Otto, Sonka Milan, Verbraak Frank D., Abràmoff Michael David.

  • Infection related and unrelated malignancies, HIV and the aging population

    Authored by: Shepherd L., Borges Áh, Ledergerber B., Domingo P., Castagna A., Rockstroh J., Knysz B., Tomazic J., Karpov I., Kirk O., Lundgren J., Mocroft A.
    In: HIV MEDICINE [aheadofprint], 2016, p. .

  • Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration

    Authored by: Sabin Caroline A., Reiss Peter, Ryom Lene, Phillips Andrew N., Weber Rainer, Law Matthew, Fontas Eric, Mocroft Amanda, de Wit Stephane, Smith Colette, Dabis Francois, D’Arminio Monforte Antonella, El Sadr Wafaa, Lundgren Jens D.
    In: BMC MEDICINE 14(1), 2016, p.61 .

  • Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment naïve HIV 1 infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort

    Authored by: Rokx C., Gras L., van de Vijver D. A. M. C., Verbon A., Rijnders B. J. A.
    In: HIV MEDICINE , 2016, p. .